Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese.
Statins have been shown to prevent coronary artery disease and to preserve left ventricular function in dilated cardiomyopathy . We hypothesized that early use of statins would decrease cardiovascular events , including heart failure in patients with acute myocardial infa rct ion ( AMI ) . To examine the effect of statins in Japanese patients with AMI , a prospect i ve , r and omized , open-label trial was conducted in 486 patients with normal total cholesterol levels . Patients were r and omly assigned to receive any available statin ( n = 241 ) within 96 hours of AMI onset or no statin ( n = 245 ) and were followed for up to 24 months . The primary end point was a composite of cardiovascular death , nonfatal AMI , recurrent symptomatic myocardial ischemia , congestive heart failure , and stroke . Event rate for the primary end point was lower in the statin group than in the nonstatin group ( 6.1 % vs 11.4 % , p = 0.0433 ) . The statin group had a lower risk of congestive heart failure and symptomatic myocardial ischemia ( p = 0.0154 and 0.0264 , respectively ) . In conclusion , early lipid-lowering therapy with statins  decreases recurrent cardiovascular events , in particular , congestive heart failure
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .